Advertisement

Topics

POLYMYXIN B SULFATE and TRIMETHOPRIM ophthalmic solution, USP sterile | POLYMYXIN B SULFATE and TRIMETHOPRIM SULFATE [Pacific Pharma, Inc.] | BioPortfolio

12:54 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Polymyxin B sulfate and trimethoprim ophthalmic solution, USP is a sterile antimicrobial solution for topical ophthalmic use.

Chemical Names: Trimethoprim sulfate, 2,4-Diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine sulfate (2:1), is

a white, odorless, crystalline powder with a molecular weight of 678.72 and the following structural formula:

Polymyxin B sulfate is the sulfate salt of polymyxin B and B which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are:

Contains: Actives: polymyxin B sulfate 10,000 units/mL; trimethoprim sulfate equivalent to 1 mg/mL.

Preservative: benzalkonium chloride 0.04 mg/mL. Inactives: purified water; sodium chloride; and sulfuric acid. May also contain sodium hydroxide for pH adjustment. It has pH of 4.0 to 6.2 and osmolality of 270 to 310 mOsm/kg.

Trimethoprim is a synthetic antibacterial drug active against a wide variety of aerobic gram-positive and

gram-negative ophthalmic pathogens. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the enzyme dihydrofolate reductase. This binding

is stronger for the bacterial enzyme than for the corresponding mammalian enzyme, and therefore, selectively interferes with bacterial biosynthesis of nucleic acids and proteins.

Polymyxin B, a cyclic lipopeptide antibiotic, is bactericidal for a variety of gram-negative organisms, especially Pseudomonas aeruginosa. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.

Blood samples were obtained from 11 human volunteers at 20 minutes, 1 hour and 3 hours following instillation in the eye of 2 drops of ophthalmic solution containing 1 mg trimethoprim and 10,000 units polymyxin B per mL. Peak serum concentrations were approximately 0.03 mcg/mL trimethoprim and 1 unit/mL polymyxin B.

In vitro studies have demonstrated that the anti-infective components of polymyxin B sulfate and trimethoprim ophthalmic solution, USP are active against the following bacterial pathogens that are capable of causing external infections of the eye:

Trimethoprim: Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus pyogenes,   Streptococcus faecalis, Streptococcus pneumoniae, Haemophilus in fluenzae, Haemophilus aegyptius, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis (indole-negative), Proteus vulgaris (indole-positive), Enterobacter aerogenes and Serratia marcescens.

Polymyxin B: Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes

and Haemophilus influenzae.

Polymyxin B sulfate and trimethoprim ophthalmic solution, USP is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus   epidermidis, Streptococcus pneumoniae, Streptococcus virida ns, Haemophilus influenzae and Pseudomonas aeruginosa.*

*Efficacy for this organism in this organ system was studied in fewer than 10 infections.

Polymyxin B sulfate and trimethoprim ophthalmic solution, USP is contraindicated in patients with known

hypersensitivity to any of its components.

NOT FOR INJECTION INTO THE EYE. If a sensitivity reaction to polymyxin B sulfate and trimethoprim

ophthalmic solution, USP occurs discontinue use. Polymyxin B sulfate and trimethoprim ophthalmic solution, USP is not indicated for the prophylaxis or treatment of ophthalmia neonatorum.

As with other antimicrobial preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.

Avoid contaminating the applicator tip with material from the eye, fingers, or other source. This precaution is necessary if the sterility of the drops is to be maintained.

If redness, irritation, swelling or pain persists or increases, discontinue use immediately and contact your physician.

Patients should be advised not to wear contact lenses if they have signs and symptoms of ocular bacterial infections.

Carcinogenesis: Long-term studies in animals to evaluate carcinogenic potential have not been conducted with polymyxin B sulfate or trimethoprim.

Mutagenesis: Trimethoprim was demonstrated to be non-mutagenic in the Ames assay. In studies at two laboratories no chromosomal damage was detected in cultured Chinese hamster ovary cells at concentrations approximately 500 times human plasma levels after oral administration; at concentrations approximately 1,000 times human plasma levels after oral administration in these same cells, a low level of chromosomal damage was induced at one of the laboratories. Studies to evaluate mutagenic potential have not been conducted with polymyxin B sulfate.

Impairment of Fertility: Polymyxin B sulfate has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.

No adverse effects on fertility or general reproductive performance were observed in rats given trimethoprim in oral dosages as high as 70 mg/kg/day for males and 14 mg/kg/day for females.

Teratogenic EffectsAnimal reproduction studies have not been conducted with polymyxin B sulfate. It is not known whether polymyxin B sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Trimethoprim has been shown to be teratogenic in the rat when given in oral doses 40 times the human dose. In some rabbit studies, the overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with oral doses 6 times the human therapeutic dose.

While there are no large well-controlled studies on the use of trimethoprim in pregnant women, Brumfitt and Pursell, in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or oral trimethoprim in combination with sulfamethoxazole. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving trimethoprim and sulfamethoxazole. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral trimethoprim and sulfamethoxazole at the time of conception or shortly thereafter.

Because trimethoprim may interfere with folic acid metabolism, trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects

The oral administration of trimethoprim to rats at a dose of 70 mg/kg/day commencing with the last third of gestation and continuing through parturition and lactation caused no deleterious effects on gestation or pup growth and survival.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when polymyxin B sulfate and trimethoprim ophthalmic solution, USP is administered to a nursing woman.

Safety and effectiveness in children below the age of 2 months have not been established (see WARNINGS).

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

The most frequent adverse reaction to polymyxin B sulfate and trimethoprim ophthalmic solution, USP is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash. Photosensitivity has been reported in patients taking oral trimethoprim.

In mild to moderate infections, instill one drop in the affected eye(s) every three hours (maximum of 6 doses per day) for a period of 7 to 10 days.

Polymyxin B sulfate and trimethoprim ophthalmic solution, USP is supplied sterile in opaque white low density polyethylene ophthalmic dispenser bottles and tips with white high impact polystyrene (HIPS) caps as follows:

10 mL in 10 mL bottle - NDC 60758-908-10

Storage: Store at 15°-25°C (59°-77°F) and protect from light.

Rx only

Revised: 12 /2018

For more information, call 1-800-678-1605

Distributed forAllergan USA, Inc.Madison, NJ 07940

© 2019 Allergan, Inc.All trademarks are the property of their respective owners

v1.0USPI908

NDC 60758-908-10

POLYMYXIN B SULFATE and TRIMETHOPRIM ophthalmicsolution, USP

10 mL

sterile Rx only

Manufacturer

Pacific Pharma, Inc.

Active Ingredients

Source

Drugs and Medications [693 Associated Drugs and Medications listed on BioPortfolio]

Bacitracin zinc and polymyxin b sulfate [stat rx usa llc]

BACITRACIN ZINC AND POLYMYXIN B SULFATE ointment [Akorn, Inc.]

Bacitracin zinc and polymyxin b sulfate [physicians total care, inc.]

NA

Bacitracin zinc and polymyxin b sulfate [rebel distributors corp.]

Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment USP, Sterile

Ak-poly-bac [direct rx]

AK-POLY-BAC

Ak-poly-bac [akorn, inc.]

Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment USP, Sterile

Clinical Trials [962 Associated Clinical Trials listed on BioPortfolio]

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

To determine the clinical efficacy of indinavir sulfate or placebo in combination with zidovudine ( AZT ) and lamivudine ( 3TC ) in AIDS patients. Protease inhibitors such as indinavir su...

A Study of Intravenous Isavuconazonium Sulfate in Pediatric Patients

The purpose of the study is to evaluate the pharmacokinetics (PK), safety and tolerability of multiple doses of intravenous (IV) isavuconazonium sulfate administered daily in pediatric pat...

Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial

All women with severe preeclmapsia were given a loading dose of 4 g magnesium sulfate IV followed by the maintenance dose of 1 g/h infusion till the delivery. After delivery, women who rec...

Bioequivalency Study of Morphine Sulfate Injection, Solution and Tablet Under Fasted Conditions

Determine the pharmacokinetics and optimize study design for subsequent studies with morphine sulfate tablets and solution.

Cellulose Sulfate (CS) Gel and HIV in Nigeria

This is a Phase 3, multi-center, randomized, placebo-controlled trial to determine the effectiveness and safety of the 6% cellulose sulfate (CS) vaginal gel for the prevention of HIV infec...

PubMed Articles [924 Associated PubMed Articles listed on BioPortfolio]

Corrigendum to "Heavy metal and sulfate removal from sulfate-rich synthetic mine drainages using sulfate reducing bacteria" Sci. Total Environ. 635 (2018) 1308-1316.

COD/sulfate ratio does not affect the methane yield and microbial diversity in anaerobic digesters.

Anaerobic digestion of organic matter is the major route of biomethane production. However, in the presence of sulfate, sulfate-reducing bacteria (SRB) typically outcompete methanogens, which may redu...

The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses.

The aim of this study was to use the liquid chromatography/tandem mass spectrometry (LC-MS/MS) method to quantitate levels of three urinary glycosaminoglycans (GAGs; dermatan sulfate [DS], heparan sul...

Direct and Simultaneous Determination of Intra-liposomal and External Sulfate in Liposomal Doxorubicin Formulations by Capillary Electrophoresis / Inductively Coupled Plasma - Tandem Mass Spectrometry (CE/ICP-MS/MS).

A capillary electrophoresis coupled to an inductively coupled plasma - tandem mass spectrometry (CE/ICP-MS/MS) method was developed and validated for the determination of external and intra-liposomal ...

Direct analysis of Pb in drinking water by liquid scintillation counting after sulfate precipitation.

Lead-210 in drinking water can be rapidly determined by liquid scintillation counting (LSC) using a new sulfate precipitation method. In this method, Pb was first preconcentrated from water using iron...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record